|
Composition for treating burns Invention represents a composition for treating burns containing oxidised dextran with molecular weight 35-65 kDa, an antiseptic, an anaesthetic, nanodiamonds with particle size 4-10 nm and a pharmaceutically acceptable filling agent with the ingredients in the composition are taken in certain proportions, wt %. |
|
|
Method of treating acute anal fissure Treating acute anal fissure involves introducing autoplasma in an amount of 2-2.5 ml under the fissure. That is preceded by 5-minute autoplasma barbotage with ozone-oxygen mixture. |
|
|
Magnetite in form of nanoparticles Invention can be used in obtaining heranostic compositions for hyperthermal treatment and/or diagnostics of tumours by means of magnetic resonance tomography. Method of polyol type for obtaining magnetite nanoparticles includes stage, at which said nanoparticles are formed in solvent -polyol, selected from glycerol or propyleneglycol. Magnetite nanoparticles are obtained from metallic iron and FeIII salts, soluble in said polyol at temperature 130-200°C, in presence of mineral acid as catalyst and water. Water is taken in molar ratio 1.5-5 times more than number of moles of applied FeIII salt. |
|
|
Method of treating dermatosis and detoxication agent for implementing it Invention refers to medicine, namely to dermatology, and describes a method of treating dermatosis based on patient's detoxication by binding toxins with using enterosorbents and discharge them. The method involves dissolving toxins and stimulating diuresis with using an infusion therapy, administering normal saline, administering a diuretic which is presented by lasix, stimulating the blood microcirculation, including at the level of small vessels with using Fraxiparine, low-molecular heparin, with the agent nadroparin calcium; the enterosorbent is Polysorb. |
|
|
Method of treating postinjection infiltrates in oncology patients From the first day a postinjection infiltrate has been found or at a later point in time, the infiltrate is exposed to infrared laser light in a constant magnetic field. The magnetic field strength falls within the range of 20-50 mT; an infrared laser pulse repetition frequency ranges within 80 Hz, whereas a transmission power is 0.25-0.5 W. The infiltrate is exposed to a defocused laser beam in the contact labile or distant labile mode at 0.3 cm for 15-25 seconds. Thereafter, tissues wetted in a hypertonic solution are applied 1-3 times a day. The therapeutic course makes 5-8 daily procedures. |
|
|
Method for pathogen inactivation Invention refers to medicine, and can be used for pathogen inactivation in biological fluid. That is ensured by mixing biological fluid with added oxygen and carbon photosensitiser representing fullerene applied on a solid-phase carrier; that is combined with exposing the mixture to optical emission. That involves using a solid-phase photosensitiser containing fullerene 0.01 wt % to 3.0 wt % per 1 g of the solid-phase carrier; the reaction mixture is additionally enriched with molecular oxygen at stirring, and thereafter the photosensitiser is separated from the reaction mixture. |
|
|
Dispersible tablet of dioctahedral smectite and method for producing it Invention refers to medicine and describes a pharmaceutical composition of dioctahedral smectite presented in the form of a dispersible tablet, as well as a method for producing it. The dispersible tablet is formed by pressing the granules containing dioctahedral smectite in an amount of 800 to 1,200 mg, as well as excipients and target additives in an amount of no more than 50% from a tablet weight. The produced tablet is water-dispersible for 3 minutes to form a dispersion consisting of particles of less than 710 mcm in size, as well as possesses high stability and physical integrity, good mechanical properties in a combination with fast dispersion ability in aqueous solutions. |
|
|
Method of obtaining particles, encapsulated in liposoluble polymer envelope of metal salts Invention relates to pharmaceutical industry, namely to method of obtaining encapsulated particles of metal salts. Method of obtaining particles of metal salts encapsulated in liposoluble polymer envelope consists in the fact that metal salt, selected from the group: iron sulphate, zinc sulphate, potassium iodide or calcium chloride, is dissolved in water, obtained mixture is dispersed in sodium carboxymethylcellulose in butanol in presence of E472c and mixed, with further addition of ethanol to obtained mixture, obtained suspension is filtered and dried at room temperature, under specified conditions. |
|
|
Invention refers to pharmaceutical industry, namely to selenium nanocomposites of natural hepatotrophic galactose-containing polysaccharide matrixes, representing water-soluble orange-red powders containing zerovalent selenium (Se0) nanoparticles sized 1-100 nm in the quantitative content of 0.5 - 60 wt %, possessing antioxidant activity for treating and preventing redox-related pathologies, particularly for treating toxic liver damage, to a method for producing and to an antioxidant agent containing the above nanocomposites. |
|
|
Method of treating patients with acne vulgaris and connective tissue dysplasia Method involves administering Aevit, Unidox as a background therapy of degree I and II, and Isotretinoin and Cynovit gel as a background therapy of degree III and IV. Besides, Magnerot® 3.0 g is taken once a day (1.0 g three times a day) throughout the all background therapy. |
|
Method is implemented as follows: preparing a mixture 1 by adding 0.5M aqueous solution of selenious acid 250 mcl in PEG 400 8 ml, mixing thoroughly in a magnetic mixture at min. 750 rpm with pH of the given mixture 7.55; that is followed by preparing a mixture 2 by adding 0.5M aqueous solution of hydrazine hydrochloride 250 mcl in PEG 400 8 ml, mixing thoroughly in a magnetic mixture at min. 750 rpm with pH of the given mixture 0.68. The mixture 1 is added to the mixture 2 by mixing thoroughly drop by drop. The prepared solution is dialysed against distilled water with removing PEG 400 and hydrazine hydrochloride; the surplus water is distilled off in a rotary evaporator at 60 rpm and 70°C. The prepared solution is added with a low-molecular compound specified in a group of: gentamicin, hexamethylene tetramine, methionine, cephalexin, indole-3-carbinol; pH is reduced to 7.2-7.4. The components are mixed in an amount to provide their content in the agent, wt %: biologically active low-molecular compound 0.001-5.0; selenium 0.0001-1.0; water up to 100. |
|
Hydrogen cocktail - lympathic drainage stimulant, method for producing it Product contains drinking water having an oxidation-reduction potential from minus 600 to minus 50 mV, total mineralisation from 25 to 130 mg/l and pH value from 6.9 to 8.3. A method for producing a lymphatic drainage stimulant involves the advanced treatment of the drinking water by passing it through a semi-permeable membrane having a hole size of 0.0001-0.005 mcm, and the molecular hydrogen saturation of the water under pressure. |
|
|
Adjuvants-diluents for live vaccines against porcine diseases Claimed invention relates to the field of veterinary and is intended for fighting porcine reproductive and respiratory syndrome (PRRS). The method includes the vaccination of pigs with PRRS with the provision of a reduction of hyperthermia duration and protection of lung integrity. The vaccine is obtained by a method, including mixing a live vaccine, prepared for immediate introduction, with an adjuvant-diluent (AD). The said adjuvant-diluent represents an "oil-in water" type emulsion, which contains per 100% of its weight: from 99 to 50 wt % of water and from 1 to 50 wt % of an oil adjuvant. The oil adjuvant contains per 100 % of its weight: from 1 to 95 wt % of at least one mineral oil and from 1 to 80 wt % of at least one SAS. The mineral oil represents oil of a Marcol or Draekol type. SAS represents an ester, obtained by the condensation of a fatty acid with sorbitol or mannitol. |
|
Method of treatment of urinogenital mycoplasmosis of dogs Method comprises subcutaneous administration of antibiotic preparation enroxyl 5% at a dose of 0.1 ml/kg daily one time a day for 7 days and intramuscular administration of homeopathic preparation ovarinin at a dose of 1 ml/kg one time for 4 days, 4-fold. |
|
Biocompatible implant (BI) made of magnetic material in a biocompatible matrix (BM) is placed loosely along a posterior surface of an injured spinal cord of an experimental animal (EA) The EA is immersed periodically into a constant magnetic field. Its magnetic vector is aligned with a craniocaudal direction of spinal tracts. The BM of the BI is animal or herbal gelatine, wherein ferromagnetic magnetite or ferromagnetic ferrite nanoparticles 18-42 wt % with a particle size of 2.0-38 nm and at a magnetic field intensity (N) of 5-10 mT are immobilised as a magnetic material of the BI. The magnetic exposure covering the traumatic spinal injuries involves the combined effect of the magnetic field of the BI and the external rotating magnetic field at a magnetic induction of 0.15-0.35 T. The external magnetic exposure frequency is 1 or 2 times a day; the length is from 2 to 8 minutes per one session; the number of sessions is from 2 to 4. Animal gelatine in the BM of the BI can represent agar-agar, whereas herbal gelatine is pectin. The BM of the BI can additionally contain polyamines contributing to cell growth and proliferation, e.g. spermine or spemidine, in an amount of 1-5 wt %. |
|
|
Method of determining duration of treatment of active forms of otosclerosis To determine density of otospongiosis focuses computer tomography of temporal bones with densitometry is carried out. Treatment duration is determined on the basis of obtained values of density. If density of otospongiosis focuses is less than 300 units HU, 4 courses of complex inactivating therapy are carried out. If density is 300-600 HU units -2 courses, if density is 600-900 units HU - 1 course. Duration of one course constitutes 3 months. During a year not more than two courses of therapy are carried out. Course of inactivating complex therapy includes intake of the following medications: bisphosphonates, sodium fluoride, calcium carbonate and vitamin D3. As bisphosphonates medication Bonviva is applied. |
|
|
Tissue nosode, preparation for treating bovine mastitis and method for using it Group of inventions refers to veterinary science and is applicable for treating bovine mastitis. What is declared is a nosode for producing a preparation for treating bovine mastitis. That involves taking mastitis milk 1 ml with clinical signs of purulent-catarrhal mastitis, filling it 70° alcohol 9 ml to produce a homogenous solution; the produced solution is diluted to "Д6" with 70° alcohol. What is also declared is a preparation for treating bovine mastitis containing an aqueous-alcoholic solution of components. The components are Belladonna, Sulphur, Apis mellifica, Conium, Phytolacca, Silicea and above nosode in the following proportions, wt %: Belladonna - 5, Sulphur - 20, Apis mellifica - 20, Conium - 10, Phytolacca - 10, Silicea - 5, nosode - 15, aqueous-alcoholic solution up to 100%. What is also declared is a method of treating bovine mastitis involving the intracisternal administration of the preparation. The preparation is administered in a dose of 5-10 ml per 1 animal once a day. |
|
Dietary supplement for preventing alcoholic intoxication and relieving alcohol withdrawal syndrome Invention represents a dietary supplement for preventing alcoholic intoxication and relieving alcohol withdrawal syndrome presented in the form of a tablet containing silicone dioxide, taurine, succinic acid and excipients; the ingredients in the tablet are taken in certain ratio, in grams. |
|
|
Method of preventing mycotoxicosis in growing broilers Invention relates to agriculture, in particular to the poultry industry and can be used for growing broilers at the poultry farms as well in private or farm enterprises. The invention provides a method of prevention of mycotoxicosis in growing broilers, which is characterised in that it comprises adding to the main ration of the feed additive - adsorbent of white slurry obtained by neutralization of the slurry with sulphuric acid to pH 6-7, which is given to broilers during the entire growing period at the doses: from the 1st to the 7th day of feeding - 2 kg per ton of combined feed, from the 8th to the 14th day - 4 kg per ton of combined feed, and from the 15th to 38th day - 6 kg per ton of combined feed. |
|
Invention relates to veterinary and can be applied in pig-breeding for the stimulation of exchange processes, growth activity, prevention of hypomicroelementosis and diarrhoeas of piglets. An energometabolic composition for the stimulation of exchange processes represents a water solution, which contains succinic acid, iodinol, beet molasses and sulphates of iron, copper, cobalt, zinc, with the following component content in 1000 ml of the solution: succinic acid - 10.0 g, iodinol - 250 ml, beet molasses - 300 ml, iron sulphate - 2 g, copper sulphate - 0.1 g, cobalt sulphate - 1 g, zinc sulphate - 0.3 g, water- the remaining part. |
|
|
Method of obtaining porous chitosan calcium phosphate-containing sponges for filling bone defects Described is a method of obtaining a composite chitosan-based material, which contains aspartic or glutamine amino acids in a quantity from 2 to 5 wt %, as well as calcium phosphates with a ratio of Ca/P from 1.0 to 1.67. The method consists in barbotage through a suspension of calcium phosphates, obtained in situ in a solution of chitosan and aspartic or glutamic acid, with the following lyophilic drying of the foamed products. Porous matrices can be applied in dentistry, maxillofacial surgery, osteoplastic surgery as implants in the treatment of bone tissue defects. |
|
Agent for treating pulp inflammation Invention represents an agent for treating a pulp inflammation differing by the fact that it contains Bezornil ointment and Dycal ivory paste in ratio 1:1 blended until smooth. |
|
|
Method of treating early breast cancer Invention can be used for treating early breast cancer (BC) involving a radical mastectomy. To this effect, blood in an amount of 8-10 ml is sampled before the surgical intervention and on the first day following the surgical intervention to detect tumour cells. If the blood is found to contain circulating tumour cells on the first postoperative day with a zero level, the therapeutic setting is added with early postoperative FAC-based polychemotherapy. |
|
|
Method of treating drug sialoadenopathy vitamins A and E, novocaine blocades of parotid salivary glands, intake of potassium iodide solution, intake of galantamine, additionally administered is "Vezugen" in a dose of 2 tablets (capsules) 2 times per day for 30 days are administered. |
|
|
Composition for prevention of metabolic disorders, increased growth activity in piglets Composition comprises succinic acid, trace elements in the form of sulphates of iron, copper, cobalt, zinc and additionally comprises methionine and beet-root molasses at the following content of components in 1000 ml of an aqueous solution: succinic acid - 5.0 g, beet-root molasses - 150.0 ml, methionine - 2.0 g, ferrous sulphate - 10.0 g, copper sulphate - 0.1 g, cobalt sulphate - 0.5 g, zinc sulphate - 0.5 g. |
|
|
Method of treating ischemic heart diseases accompanying cholestasis Antianginal therapy is accompanied by a primary discrete plasmapheresis in a refrigerate centrifuge PC-6 having a rotating speed of 2,000 rpm for 15 minutes at a temperature of 22°C in number of 5 sessions every second day. One session involves removing the whole blood in an amount of: 2 flexible PVC packages x 450 ml if the patient's body weight index is from 18 to 29.9 kg/m2, 3 flexible PVC packages x 450 ml if the patient's body weight index is over 30 kg/m2. The total volume of the removed plasma makes 600-900 ml. The circulating blood volume is replaced with 0.9% NaCl in an amount of half as much as the removed plasma volume. Once the plasmapheresis course is completed, the blood is exposed to ultraviolet light generated by OVK-3 apparatus for at wave length more than 400 nm in number of 5 procedures every second day. |
|
Group of inventions relates to medicine, namely to dermatology and mycology, and can be applied in the treatment of skin and its appendages. A pharmaceutical composition for external application contains nanoparticles for the laser thermotherapy of infectious affections of the skin and its appendages. The nanoparticles are characterised by, at least, one localised surface Plasmon resonance in the range of a wavelength from 400 to 1100 nm. The nanoparticles are dispersed in a physiologically acceptable carrier, which is characterised by the absence of the absorption or weak absorption and/or weak dispersion of light radiation in the said range of wavelengths and possessing biocidal properties. The pharmaceutical composition is applied on an affected area and irradiated by laser radiation with a wavelength close to the wavelength of the localised surface Plasmon resonance of the nanoparticles, contained in the composition, or equal to it. The irradiation is continued until the desirable temperature of heating of the said area is achieved. |
|
Ointment for septic and open wounds Ointment contains wax 13-15 wt %, glycerol 15-20 % and vegetable oil; the prepared ointment mass is exposed to ozone for 15-20 min in a yield amount of 10 mg/l. |
|
|
Invention refers to pharmaceutical industry, namely to a method for producing a complex compound of dihydroquercetin with metal ions specified in zinc, copper (II) or calcium possessing antioxidant activity. A method consists in the fact that dihydroquercetin and metal salt is mixed in the dry state in a reactor in certain molar ratio; that is followed by adding water at a certain temperature or ethanol or aqueous-alcoholic solution at a room temperature at the controlled medium acidity; using metal salts containing weak acid anions provides medium pH equal to 5.0-5.6; using the metal salts containing strong acid anions requires reducing pH to 7 by adding an alkaline solution; the reaction is completed almost immediately for the first 5 minutes; the precipitation is filtered in water and/or ethanol; dried in air, then in a drying box to constant weight, and a complex compound is produced. The declared method enables reducing the production costs substantially and cheapening the technological process in achieving the target yield with the preset properties. |
|
Method for surgical management of clinical outcome of retinal venous thrombosis Method involves performing a vitrectomy with removing a posterior hyaloids of a vitreous body, and a laser retinal endocoagulation at wave length 532 nm, emitting power 120-200 mWt, pulse length 0.1-0.2 s, spot diameter 150-200 mcm. A chorioretinal venous anastomosis (CRVA) is induced by exposing the branches of the central vein of the retina to the third-order laser light at wave length 532 nm in a number of 4 coagulated, emitting power 500 mWt, pulse length 1 sec and spot diameter 50 mcm. The vitrectomy is preceded by the intramuscular injections of 12.5% etamylate 4ml and the intravenous administration of 0.5% tranexamic acid 1 g 25-30 minutes before. That is followed by the droplet intravenous administration of an infusion solution containing 0.1% perlinganit 10 ml in 0.9% normal saline 100 ml at an initial rate of 5 mcg/min. The area to be exposed to laser is specified at least in 3 diameters of the disk from the optic disk. The third-order laser applications are applied on the branches of the central vein of the retina in a number from 2 to 4 at wave length 532 nm, emitting power 300-400 mWt, exposure 0.5 s, spot diameter 500 mcm in two points in the proximal and distal direction from the CRVA induction point. Immediately before the CRVA induction, a salt-water infusion flow is increased until the central retinal artery starts pulsating. The surgical management is completed by plugging the vitreal cavity with 20% air-gas mixture SF6. |
|
|
Method for early postoperative treatment of chronic rhinosinusitis Invention represents a method for early postoperative treatment of chronic rhinosinusitis involves a pre-anemisation of a nasal mucosa with an adrenalin solution, a decrustation involves by the fact that the decrustation is followed by administering the preparation 'Argogel' 1.0 ml 2 times a day for 10 minutes throughout 2 weeks. |
|
Method of burn wounds treatment Invention relates to medicine, namely to combustiology, and can be applied in process of treating burn wounds of III a and III b degree. For this purpose applied are cultured dermal allofibroblasts on 5-8 passage with concentration 250000 cells/ml as part of composition, which includes as carrier hydroxyethylcellulose natrosol and native collagen. After uniform distribution of medication on wound surface relief fixing with inert mesh covering "Lomatul-N" is carried out. |
|
Method of bone tissue substitution Described is a method of bone tissue substitution, in which as a bone-substituting material applied is a biodegradable material of the following composition, wt %: biological hydroxyapatite - 50-52, magnesium phosphate - 30-32, calcium hydrophosphate - 8-10, calcium hydroxide - 4.8-5.3, sodium alginate - the remaining part. As a binding agent applied is casein in the form of an ammonia solution with the ratio of powder mass of the biodegradable material to the ammonia casein solution of 1:1-1.5. |
|
Antiseptic compositions and applications thereof Group of inventions refers to antiseptic compositions and applicable for disinfection of surfaces, such as body surfaces, and for treatment of infection-related conditions. As active ingredients, an antiseptic composition contains menthol and silver ions, and a pharmaceutically acceptable carrier. The silver ion concentration in the composition makes from 0.25 mM to 0.6 mM, whereas the menthol concentration makes from 0.64 mM to 6.4 mM. What is also presented is an antiseptic kit containing the above composition and a packaging material. Other embodiments involve a method for producing the above antiseptic composition, a method for reducing the silver ion concentration in the antiseptic composition and a method for increasing the antiseptic activity of the above composition. |
|
Method of increasing biological properties of antiseptic-stimulator of dorogov asd-2f Increase in biocidal and immunobiological action due to the use of distilled water ionised with silver ions and adding into the composition of succinic, ascorbic, citric acid and aethonium. |
|
Method of producing lithium chloride microcapsules having supramolecular properties Invention relates to encapsulation. A method of producing lithium chloride microcapsules in a sodium alginate envelope comprises: adding a suspension of lithium chloride in benzene to a suspension of sodium alginate in butanol in the presence of an E472c preparation while stirring at 1200 rps; the lithium chloride and said polymer are taken in weight ratio of 1:1 or 1:3; adding chloroform; and filtering and drying the obtained suspension of microcapsules. The process of producing the microcapsules is carried out at room temperature for 10 minutes. |
|
Method for correcting bone tissue status and preventing fractures in cardiovascular patients Invention refers to medicine, namely to orthopaedics, and can be used for correcting the bone tissue status and preventing fractures in cardiovascular patients. That is ensured by administering Calcemin advance 1 tablet 1-3 times a day with meals for 6 months. |
|
Method of treating locally advanced stomach cancer with high metabolic and proliferative activity CEA, CA 19-9, CA 72-4, M2-PK cancer-specific markers and Ki-67 proliferation index are pre-determined; combined positron emission and computer tomography (PET/CT) are performed. Up to two procedures of neoadjuvant intra-arterial chemoembolisation are conducted with the first one performed by administering a half single systemic dose of irinotecan in lipiodol 4-6 ml; no sooner than 2-3 weeks later, the cancer-specific markers and Ki-67 proliferation index and PET/CT SUVmax are checked; if at least one of this factors tends to increase as compared to references, the intra-arterial chemoembolisation is conducted again by administering at least 1/3 single systemic dose of irinotecan in no more than lipiodol 5 ml. Not later than 10-14 days following the second chemoembolisation or no sooner than 2-3 weeks after the first chemoembolisation, a surgical intervention is required if the tumour keeps its metabolic and proliferative activity on these days. |
|
Method of prevention of technological stresses in lambs at weaning Method comprises administering the preparation in a dose of 0.5 ml/25 kg live weight. The preparation is administered two times intramuscularly with an interval of 35 days. The first administration of the preparation is carried out 35 days before weaning, and the second - at the time of weaning the lambs. The preparation is used as a vitamin and mineral complex containing selenium taken in nanoscale state and zero valence of 0.125%, fat-soluble vitamin E 3.8%, water-soluble vitamin B1 0.1%, water-soluble vitamin B2 0.1%, water-soluble vitamin B5 0.1%, water-soluble vitamin B6 0.1%, water-soluble vitamin B12 0.1%, vitamin K3 - 0.1%, solubiliser Solutol HS 15 1.0-20.0%, and water. |
|
|
Method for treating residual cavity following marsupialisation and open echinococcectomy Two-duct drain tube is intraoperatively inserted into a residual cavity. The tube is delivered onto an anterior abdominal wall. The cyst cavity is irrigated with 0.05% chlorhexidine every day from the second postoperative day that is followed by administering the preparation of 10% povidone iodine with the drain tube pinched for 3-5 minutes. The procedure is performed until the cyst cavity is eliminated completely. |
|
Plasma-adapted balanced solution of electrolytes Invention relates to field of pharmaceutics and deals with application of aqueous balanced solution of electrolytes as external washing solution, for washing and purification in case of surgery, for washing and purification of wounds and burns, for washing body cavities, for eye washing, for washing and purification of instruments and in servicing stomas or as carrier solution for compatible electrolytes, nutrients and medications. Aqueous balanced solution contains: 138-146 mmol/l of sodium, 4-5 mmol/l of potassium, 0.5-2.0 mmol/l calcium, 1.0-1.5 mmol/l of magnesium, 100-108 mmol/l of chloride, 0.5-1.5 mmol/l of phosphate, 18-26 mmol/l of gluconate, 20-28 mmol/l of acetate. |
|
|
Formulation of cough medical composition and method for producing it Invention refers to the pharmaceutical industry, namely to a formulation of a cough medical composition. The formulation of the cough medical composition contains an active substance presented by thermopsis herb powder or a dry extract of thermopsis and sodium hydrocarbonate, as well as an excipient, a granulating agent and a lubricant taken in certain relations (versions). |
|
|
Disclosed cloth is capable of inactivating viruses falling thereon even in the presence of lipids and proteins regardless of whether or not the viruses have an envelope. The cloth is capable of inactivating viruses falling thereon and includes a cloth base and fine particles of a monovalent copper compound and/or iodide fine particles, wherein the fine particles of a monovalent copper compound and/or iodide fine particles are deposited on said cloth base. The fine particles of the monovalent copper compound are particles of at least one of the following group: chloride, acetate, sulphide, iodide, bromide, peroxide and thiocyanate. The cloth is capable of inactivating different types of viruses. The viruses are inactivated even in the presence of lipids and proteins. |
|
Method of obtaining calcium carbonate Calcium carbonate is precipitated by reaction of water solutions of calcium salts with water solutions of carbonates in presence of non-ionogenic surface-active substance at temperature not less than 85°C. Then calcium carbonate is separated from solution by filtration. Soluble phosphates are added into water solutions of carbonates with molar ratio of phosphates to carbonates 1:100-1:20, and liquid glass is added into water solutions of calcium salts with molar ratio of liquid glass to calcium salts 1:1000-1:100. As water solutions of carbonates, solutions of potassium carbonate or sodium carbonate are applied. As soluble phosphates, potassium hydrophosphate or potassium dihydrophosphate are applied, and as water solutions of calcium salts, solutions of calcium chloride or calcium nitrate are applied. |
|
Method of preparing mixture of vetom 1,1 and sel-plex, having supramolecular properties Invention relates to encapsulation, particularly a method of producing microcapsules of a mixture of Vetom 1.1 and Sel-Plex in a carrageenan envelope. According to the disclosed method, Vetom 1.1 and Sel-Plex, taken in weight ratio of 60:40, are dissolved in dimethyl sulphoxide or dimethyl formamide. The obtained mixture is dispersed in carrageenan solution in benzene in the presence of an E472c preparation while mixing at 1000 rps. The mixture of the preparations and carrageenan are taken in weight ratio of 1:1 to 1:5. Butanol and distilled water, taken in ratio of 5:1 vol/vol, are then added. The obtained suspension of microcapsules is filtered out and dried. The process of producing the microcapsules is carried out at 25°C for 20 minutes. |
|
Method of prevention and treatment of gastritis, stomach and duodenal ulcer Invention relates to medicine, namely to gastroenterology, and deals with the treatment of gastritis, stomach and duodenal ulcer. For this purpose a water solution of high-dispersive cluster silver with the concentration of 0.05-0.5 mg/ml is introduced inside in a dose of 30-50 ml 1-2 times per day for 10-30 days, or is applied on an injury focus in the process of endoscopic examination. In the latter case the solution of high-dispersive cluster silver with the concentration of 0.5-1.0 mg/ml is applied in a dose of 3-10 ml depending on the size of the injury focus. |
|
|
Method of treating preeclampsia of moderate severity in women with alimentary obesity For patient with alimentary obesity preliminarily determined are: clearance of osmotically free water (CFW) and colloid oncotic pressure (COP). If CFW level is lower than -0.45 ml/min and COP is lower than 18 mm Hg, therapy starts from intravenous introduction of 6% HES "Voluven" in dose 6.5 ml/kg/day at rate 350 ml/h. Immediately after the end of infusion introduction with syringe doser of 25% solution of magnesium sulphate in dose 0.75 ml/kg/day at rate 2.8 ml/h. For patient without obesity, if CFW level is lower than -0.6 ml/min and COP is lower than 21 mm Hg, therapy is started from intravenous introduction of 6% HES "Voluven" in dose 5.5 ml/kg/day at rate 300 ml/h. 25% solution of magnesium sulphate in dose 0.9 ml/kg/day at rate 2.4 ml/h is also introduced by means of syringe doser. Treatment is carried out during a day. |
|
|
Invention refers to medicine, more specifically to clinical dentistry. The invention represents a composition for treating erosive ulcerative and exudative hyperaemic forms of oral lichen planus. |
|
Method for producing an agent for stimulating body cells involving preparing a mixture of aqueous solution of selenious acid and PEG 400; that is followed by preparing a mixture of hydrazine hydrochloride and PEG 400; the prepared mixtures are combined; the solution is put to dialyse against distilled water; surplus of water is driven off; the produced solution is added with hexamethylene tetramine; pH is reduced to 7.2-7.4; the method is implemented in certain circumstances. |
|
Method for producing silymarin and nanoselenium agent having inhibitory action of tumour cell growth Method for producing an agent inhibitory the tumour cell growth, involving preparing a mixture of aqueous solution of selenious acid and PEG 400; that is followed by preparing a mixture of aqueous solution of hydrazine hydrochloride and PEG 400; the produced mixtures are combined; the solution is put to dialyse against distilled water; surplus of water is driven off in a rotary evaporator; the produced solution is added with silymarin dissolved in Solufor with dialysis against distilled water; pH is reduced to 7.2-7.4; the method is implemented in certain circumstances. |
Another patent 2551279.